Context Therapeutics (CNTX) 10-Q2023 Q1 Quarterly report

Filed: 10 May 23, 4:34pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: alternative, announced, challenging, closeout, costly, decided, Disposal, exceeded, Exit, explore, extensive, firm, focusing, harm, human, increasingly, intent, lack, landscape, lung, mandatory, outflow, Oversight, prioritization, remove, renew, rotation, slightly, solid, submit, testicular

Removed: advancing, agent, aggregate, Aid, anastrozole, anniversary, antagonist, applied, Bank, bore, borrower, cancelled, carryforward, carryover, cell, Center, Chief, classification, closed, closing, collectively, combined, comparability, converted, declared, decrease, deferral, depository, determination, director, earliest, effectively, embedded, endometrial, entirety, evaluate, existence, family, Flexibility, forgiven, foundation, fulvestrant, global, granulosa, grow, gynecologic, half, Health, holder, imaging, implemented, innovative, Jefferson, Kettering, leasing, lender, line, linked, loan, mature, member, membership, Memorial, merger, metastatic, modified, monthly, Network, occurred, Oncology, optional, Organization, Pacific, package, Paycheck, pipeline, potent, PR, practical, preliminary, progesterone, progression, radiolabeled, receptor, recognizing, record, recurrent, redeemable, Relief, resistance, resulted, reverse, RSU, Security, Seed, select, selective, Senior, September, Sloan, Small, standard, synergy, Targeted, transaction, transparency, treating, treatment, triangular, unpaid, uterine, warrant, Western, Wisconsin, women

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

CNTX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATIONS PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350, as adopted), Martin Lehr, Chief Executive Officer (Principal Executive Officer) of Context Therapeutics Inc. (the “Company”), and Jennifer Minai-Azary, Chief Financial Officer (Principal Financial Officer) of the Company, each hereby certifies that, to the best of his or her knowledge:

(1) The Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 (the “Quarterly Report”), and to which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended, and

(2) The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.


			/s/ Martin Lehr
Date: May 10, 2023			Martin Lehr
			Chief Executive Officer (Principal Executive Officer)

			/s/ Jennifer Minai-Azary
Date: May 10, 2023			Jennifer Minai-Azary
			Chief Financial Officer (Principal Financial Officer)

“This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Context Therapeutics Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.”